HK1194922A1 - -核糖 聚合酶的抑制劑 - Google Patents

-核糖 聚合酶的抑制劑

Info

Publication number
HK1194922A1
HK1194922A1 HK14108469.9A HK14108469A HK1194922A1 HK 1194922 A1 HK1194922 A1 HK 1194922A1 HK 14108469 A HK14108469 A HK 14108469A HK 1194922 A1 HK1194922 A1 HK 1194922A1
Authority
HK
Hong Kong
Prior art keywords
adp
ribose
polymerase
inhibitors
poly
Prior art date
Application number
HK14108469.9A
Other languages
English (en)
Inventor
Viraj B Gandhi
Vincent L Giranda
Jianchun Gong
Thomas D Penning
Gui-Dong Zhu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1194922(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1194922A1 publication Critical patent/HK1194922A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Hematology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK14108469.9A 2006-12-28 2014-08-19 -核糖 聚合酶的抑制劑 HK1194922A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88231706P 2006-12-28 2006-12-28

Publications (1)

Publication Number Publication Date
HK1194922A1 true HK1194922A1 (zh) 2014-10-31

Family

ID=39584870

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14108469.9A HK1194922A1 (zh) 2006-12-28 2014-08-19 -核糖 聚合酶的抑制劑

Country Status (31)

Country Link
US (1) US20080161280A1 (zh)
EP (2) EP2698062B1 (zh)
JP (2) JP5523837B2 (zh)
KR (2) KR101449436B1 (zh)
CN (2) CN103690542B (zh)
AU (1) AU2007340020B2 (zh)
BR (1) BRPI0722070A2 (zh)
CA (1) CA2672868C (zh)
CO (1) CO6220961A2 (zh)
CR (1) CR10901A (zh)
DK (2) DK2698062T3 (zh)
DO (1) DOP2009000159A (zh)
EC (1) ECSP099530A (zh)
ES (2) ES2442496T3 (zh)
GT (1) GT200900182A (zh)
HK (1) HK1194922A1 (zh)
HR (1) HRP20140115T1 (zh)
HU (1) HUE027641T2 (zh)
MX (2) MX2009007051A (zh)
MY (2) MY190838A (zh)
NO (1) NO20092698L (zh)
NZ (2) NZ577348A (zh)
PL (2) PL2120579T3 (zh)
PT (2) PT2698062E (zh)
RS (1) RS53196B (zh)
RU (1) RU2455286C2 (zh)
SG (2) SG193664A1 (zh)
SI (2) SI2698062T1 (zh)
TW (1) TWI429438B (zh)
UA (1) UA97506C2 (zh)
WO (1) WO2008083027A1 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
EP2155689B1 (en) 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
RU2010108008A (ru) * 2007-09-14 2011-10-20 Астразенека Аб (Se) Фталазиноновые производные
US8268827B2 (en) * 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
BRPI0920604B1 (pt) 2008-10-07 2021-11-23 Kudos Pharmaceuticals Limited Formulação farmacêutica de liberação imediata na forma de uma dispersão sólida compreendendo como ativo o composto 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona (olaparibe)
US20120053164A1 (en) 2008-12-19 2012-03-01 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
MA33053B1 (fr) * 2009-01-23 2012-02-01 Tadeka Pharmaceutical Company Ltd Inhibiteurs de la poly(adp-ribose) polymerase (parp)
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
EP2600867A1 (en) * 2010-08-03 2013-06-12 Nerviano Medical Sciences S.r.l. Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
AU2012243132A1 (en) 2011-04-11 2013-10-24 Abbvie Inc. PARP inhibitors for the treatment of CIPN
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
TWI548637B (zh) * 2011-07-26 2016-09-11 江蘇豪森藥業集團有限公司 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
WO2013028818A1 (en) 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Pyrimido- pyridazinone compounds and use thereof
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
ES2614885T3 (es) 2012-12-31 2017-06-02 Cadila Healthcare Limited Derivados sustituidos de ftalazin 1(2H) ona como inhibidores selectivos de la poli(ADP ribosa) polimerasa 1
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
EP3317270B1 (en) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP3481816B1 (en) * 2016-07-07 2020-06-24 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
TW202244048A (zh) 2017-03-20 2022-11-16 美商佛瑪治療公司 作為丙酮酸激酶（ｐｋｒ）活化劑之吡咯并吡咯組成物
KR102586510B1 (ko) 2018-02-13 2023-10-12 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN114040910A (zh) * 2019-07-10 2022-02-11 拜耳公司 制备2-(苯基亚氨基)-1,3-噻唑烷-4-酮的方法
CA3176219A1 (en) 2020-04-21 2021-10-28 Kunhee LEE Crystalline forms of phthalazinone compound
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US20220117961A1 (en) * 2020-10-16 2022-04-21 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US20240150345A1 (en) * 2021-01-22 2024-05-09 Hibercell, Inc. Gcn2 modulating compounds and uses thereof
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023278222A1 (en) * 2021-06-28 2023-01-05 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
EP1423120A4 (en) * 2001-08-15 2005-12-28 Icos Corp 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
DE60336890D1 (de) * 2002-02-19 2011-06-09 Ono Pharmaceutical Co Kondensierte pyridazinderivat-verbindungen und die verbindungen als wirkstoff enthaltende arzneimittel
EP1501822B1 (en) * 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
EA014955B1 (ru) * 2004-06-30 2011-04-29 Янссен Фармацевтика Н. В. Производные фталазина в качестве ингибиторов parp
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
AR064424A1 (es) * 2006-12-20 2009-04-01 Glaxo Group Ltd Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio.
MX2009011421A (es) * 2007-04-23 2009-12-15 Novartis Ag Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
RU2010108008A (ru) * 2007-09-14 2011-10-20 Астразенека Аб (Se) Фталазиноновые производные
JP2011500537A (ja) * 2007-10-11 2011-01-06 グラクソ グループ リミテッド Ｈ１受容体アンタゴニストとしてのフタラジンおよびピリド［３，４−ｄ］ピリダジン化合物

Also Published As

Publication number Publication date
MY190838A (en) 2022-05-12
SI2698062T1 (sl) 2015-12-31
CA2672868A1 (en) 2008-07-10
HRP20140115T1 (hr) 2014-03-14
CN101641014A (zh) 2010-02-03
KR101491998B1 (ko) 2015-02-10
DK2120579T3 (da) 2014-02-03
KR101449436B1 (ko) 2014-10-14
EP2120579A4 (en) 2011-04-27
RU2009128984A (ru) 2011-02-10
MX2009007051A (es) 2009-07-10
ES2548353T3 (es) 2015-10-15
HUE027641T2 (en) 2016-11-28
PT2698062E (pt) 2015-10-19
JP2010514785A (ja) 2010-05-06
ECSP099530A (es) 2009-08-28
RU2455286C2 (ru) 2012-07-10
ES2442496T3 (es) 2014-02-11
EP2698062A1 (en) 2014-02-19
CN103690542A (zh) 2014-04-02
RS53196B (en) 2014-06-30
DOP2009000159A (es) 2015-11-30
PL2698062T3 (pl) 2015-12-31
EP2120579A1 (en) 2009-11-25
SI2120579T1 (sl) 2014-03-31
EP2120579B1 (en) 2013-11-13
PL2120579T3 (pl) 2014-04-30
CA2672868C (en) 2015-11-24
GT200900182A (es) 2010-02-19
WO2008083027A1 (en) 2008-07-10
AU2007340020A1 (en) 2008-07-10
NZ577348A (en) 2012-04-27
KR20140056395A (ko) 2014-05-09
TW200840579A (en) 2008-10-16
AU2007340020B2 (en) 2013-06-20
SG2014013411A (en) 2014-07-30
MY165570A (en) 2018-04-05
BRPI0722070A2 (pt) 2014-04-08
KR20090094116A (ko) 2009-09-03
PT2120579E (pt) 2014-02-17
DK2698062T3 (en) 2015-09-14
SG193664A1 (en) 2013-10-30
US20080161280A1 (en) 2008-07-03
CN101641014B (zh) 2013-12-18
UA97506C2 (en) 2012-02-27
CO6220961A2 (es) 2010-11-19
TWI429438B (zh) 2014-03-11
JP5523837B2 (ja) 2014-06-18
CR10901A (es) 2009-07-23
CN103690542B (zh) 2015-11-18
NO20092698L (no) 2009-09-28
MX347085B (es) 2017-04-06
JP2014001209A (ja) 2014-01-09
NZ598352A (en) 2013-08-30
EP2698062B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
HK1194922A1 (zh) -核糖 聚合酶的抑制劑
HUS1900053I1 (hu) A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai
IL195031A0 (en) Uses of dpp-iv inhibitors
GB0813961D0 (en) Swab
GB0621607D0 (en) Inhibitors of c-Met
ZA200805855B (en) Viral polymerase inhibitors
GB0608823D0 (en) Inhibitors of P13 kinase
SI2094702T1 (sl) Virusni inhibitorji
GB0705854D0 (en) Methods of construction
IL197023A0 (en) Viral polymerase inhibitors
IL197981A0 (en) Kinase inhibitors
ZA200903996B (en) Inhibitors of poly (adp-ribose)polymerase
HU0600159D0 (en) Kvantitative pcr
GB0622367D0 (en) Phosphodiesterase inhibitors
GB0621107D0 (en) Inhibitors of phosphodiesterase-4
GB0617565D0 (en) Polymerase
GB0621094D0 (en) Polymerase
GB0623977D0 (en) Polymerase
GB0621980D0 (en) Inhibitors of c-Met
GB0621606D0 (en) Inhibitors of p13 kinase

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191223